Article

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

2025-10-05

Abstract excerpt

<title>Abstract</title> <p>Platinum-resistant epithelial ovarian cancer (EOC) represents a population with limited therapeutic options. We conducted a proof-of-concept, phase II single-center, multi-arm study of durvalumab plus cediranib (D + C) or durvalumab, cediranib, and olaparib (D + O + C) in recurrent EOC. Sixty-eight patients were enrolled (D + O + C [n = 39] and D + C [n = 29]). Pre- and on-treatment bio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5deee25b-c1dc-540d-929c-50c39677770c
DOI: 10.21203/rs.3.rs-7724642/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerDOI 10.21203/rs.3.rs-7724642/v1Read

Identification of platinum-resistance related small GTPase binding signatures to predict the prognosis of ovarian cancer by machine learning and integrated bioinformatic analysesSemantic proximity Read

Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian CancerSemantic proximity Read

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.Semantic proximity Read

A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common CancersSemantic proximity Read

Proteomic landscape of epithelial ovarian cancer.Semantic proximity Read

The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free intervalSemantic proximity Read

Identification an novel classification and nomogram of programmed cell-death patterns for investigating the immune microenvironment and prognosis of postoperative ovarian cancer patientsSemantic proximity Read

Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian CancerSemantic proximity Read

Ovarian cancer: emerging molecular-targeted therapiesSemantic proximity Read

Identification machine learning-based model of programmed cell-death patterns for investigating the immune microenvironment and prognosis of ovarian cancer patients after surgery and providing therapeutic strategiesSemantic proximity Read

The putative effects of carboplatin based neoadjuvant chemotherapy on tumor microenvironment of epithelial ovarian carcinomaSemantic proximity Read

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaSemantic proximity Read